[
    [
        {
            "time": "2018-03-15",
            "original_text": "AbbVie: The Right Mixture for the Perfect Stock",
            "features": {
                "keywords": [
                    "AbbVie",
                    "right mixture",
                    "perfect stock"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie: The Right Mixture for the Perfect Stock",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2019-08-07",
            "original_text": "CytomX Therapeutics, Inc. (CTMX) Q2 2019 Earnings Call Transcript",
            "features": {
                "keywords": [
                    "CytomX Therapeutics",
                    "Q2 2019",
                    "earnings call",
                    "transcript"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "CytomX Therapeutics, Inc. (CTMX) Q2 2019 Earnings Call Transcript",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 2,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        }
    ]
]